妇科细胞学质量保证实践模式:2022年CAP PAP教育计划参与实验室调查
该研究通过补充问卷评估参与2022年CAP妇科细胞病理学教育计划的实验室在妇科细胞学质量保证指标上的实践模式。共562家实验室回复,511家纳入分析。多数实验室将既往未治疗异常细胞学或异常妇科活检视为高风险需负复筛,85.3%要求病理医师复核特定指征的Pap涂片,62.5%通过显著细胞-组织学不一致评估病理医师表现。
要点
- 78.5%实验室将既往未治疗异常细胞学Pap涂片视为高风险需负复筛。
- 85.3%实验室要求病理医师复核反应性/异常细胞以外指征的Pap涂片。
- 62.5%实验室通过显著细胞-组织学不一致评估病理医师表现。
核心结论
- CAP调查详细评估了妇科细胞学当前质量保证实践,可帮助实验室改进其质量保证决策。
- 随着宫颈癌筛查指南和工具演变,质量保证指标需相应细化。
研究设计与样本
- 补充问卷邮寄给参与2022年CAP妇科细胞病理学(PAP教育)计划的实验室,收集妇科细胞学质量保证措施数据。
- 共562家实验室回复,511家实验室的回复进一步分析。
主要发现
- 在492家实验室中,386家(78.5%)将既往一年未治疗异常细胞学患者的Pap涂片视为高风险需负复筛。
- 在492家实验室中,331家(67.3%)将并发或过去一年内异常妇科活检患者的Pap涂片视为高风险需负复筛。
- 511家实验室中436家(85.3%)要求病理医师复核反应性/异常细胞以外指征的Pap涂片,如45岁及以上女性子宫内膜细胞。
- 451家回复中399家(88.5%)记录细胞学技师与病理医师判读不一致率以评估技师表现。
- 389家实验室中243家(62.5%)通过显著细胞-组织学不一致病例评估病理医师表现。
临床怎么用
- 实验室可参考调查结果优化妇科细胞学质量保证指标,如高风险负复筛指征和病理医师复核范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT.—: Though numerous quality assurance (QA) measures are in place for the practice of gynecologic cytopathology, many of them are not clearly defined and may be variably used by laboratories worldwide. OBJECTIVE.—: To assess current practice patterns regarding the implementation of selected gynecologic cytology QA metrics to help develop guidance for laboratories. DESIGN.—: A supplemental questionnaire was mailed to laboratories participating in the 2022 College of American Pathologists (CAP) Gynecologic Cytopathology (PAP Education) Program requesting data regarding their QA measures in gynecologic cytology. RESULTS.—: A total of 562 laboratories responded to the supplemental questionnaire; responses from 511 laboratories were analyzed further. Of 492 laboratories, most considered Papanicolaou (Pap) tests from patients with untreated abnormal cytology in the previous year (386; 78.5%) or with an abnormal gynecologic biopsy finding (concurrent or within the past year) (331; 67.3%) as high-risk for negative rescreening. Many laboratories (436 of 511; 85.3%) required pathologist review of Pap tests for indications other than reactive/abnormal cells (eg, endometrial cells in women 45 years of age and older). For assessing cytologists' performance, 88.5% (399 of 451) of respondents recorded the discrepancy rate between cytologist's and pathologist's interpretations. For monitoring pathologists' performance, most laboratories (243 of 389; 62.5%) evaluated cases with significant cytologic-histologic discrepancy. CONCLUSIONS.—: The CAP survey provided a detailed assessment of current QA practices regarding gynecologic cytology, which can aid laboratories in making decisions related to enhancement of QA in their setting. As the guidelines and tools for cervical cancer screening evolve, QA metrics will need to be accordingly refined.
引用
- Goyal A, Davey DD, Souers RJ, et al. Practice Patterns Regarding Quality Assurance Measures in Gynecologic Cytology: Survey Results of Laboratories Participating in the 2022 College of American Pathologists PAP Education Program. Arch Pathol Lab Med. 2025. PMID: 41042178. doi:10.5858/arpa.2025-0187-CP
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。